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Under certain pathologic conditions AGEs formation can be increased
beyond normal levels.The purpose of the study was to investigate essential
RF and AGEs before, immediately after and 2 days after runs. Nine trained
runners (4379yr) during 9.5 km and 13 trained runners (48711yr)
during 16.3 km long-distance runs were investigated. Standard blood and
urinary RF parameters were investi-gated in all runners using
spectrophotometric methods by Roche analyzer Integra 800.Serum cystatin
C was determined using immu-noturbidimetric method (PETIA Gentian).
Plasma AGEs and malon-dialdehyde (MDA) were determined by
spectroﬂuorimetric methods, Ne-carboxylmethyllysine using ELISA method
and advanced oxidation protein products(AOPPs) using
spectrophotometric method.
Total proteinuria was 0.4670.4 g/L after 9.5 km run and 0.3570.3 g/L
after 16.3 km run. Serum urea and creatinine signiﬁcantly increased after
both runs (creatinine in 28% after 9.5 km and in 41% after 16.3 km run).
Estimated glomerular ﬁltration rate (eGFR) MDRD and eGFR-PETIA
signiﬁcantly decreased after both runs (9.5 km: in 27.6% resp. 21.3% and
16.3 km: in 34,6% resp. 30.3%, po0.01). Direct relationship between serum
cystatin C and plasma AGEs after 16.3 km run was found (r¼0.66, p¼
0,014). No signiﬁcant changes in plasma AGEs (from 277786—2867
72 resp. from 283764—292790 AU), CML (from 619778–6657131
resp. from 724792—7627135 ng/mL) and AOPPs (from 151758—1067
21 resp. from 1597100–133767 mmol/L) were found after both runs.
Plasma MDA decreased after both runs.
In conclusion, RF abnormalities in runners were caused by dehydration,
protein catabolism, rhabdomyolysis and others. These RF changes were not
present or parameters not signiﬁcantly differed from initial values 2 days
after both runs. Plasma AGEs and AOPPs in runners were in reference
ranges, no signiﬁcant changes during the both runs were observed.
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Peginesatide is an erythropoiesis stimulating agent (ESA) being developed for
the treatment of anemia due to chronic kidney disease in dialysis patients. The
purpose of this analysis was to develop a population PK-PD model to
characterize time-course of peginesatide plasma and hemoglobin (Hb)
concentrations following administration of IV and SC peginesatide injections.
This population PK–PD analysis included 4 phase 2 studies and 1 phase 3 study.
Baseline subject demographics, laboratory values, and concomitant
medications were evaluated as covariates in a stepwise manner. Models were
evaluated for goodness-of-ﬁt using diagnostic plots, predictability based on
visual predictive check, and stability based on bootstrap analyses. The ﬁnal PK
model was a two compartment model with ﬁrst-order absorption and
saturable elimination. The ﬁnal PD model was a precursor-dependent indirect
response model with parameters accounting for the residual effect from the
previous ESA doses (ESAD) and apparent change in disease condition (CF). The
PD parameters shown below were estimated with good precision(relative
standard error[RSE] r2%).Parameters Estimate RSE%EC50 (ng/mL) 401 2.0
Emax 0.542 1.6
Baseline Hb (g/dL) 11.5 0.40
MTT (mean transit time for red blood cells, h) 1640 0.49
MTP (mean transit time for progenitor cells, h) 462 1.1
ESA (residual effect from the previous ESA 0.153 0.66
CF (correction factor for disease condition) 0.000275 0.87Total bilirubin, body mass index, age, alkaline phosphatase, ethnicity, and
serum creatinine (for non-dialysis subjects) for PK and age and ESAD for PD
were identiﬁed as statistically signiﬁcant (p-valueo0.005) covariates.
None of these identiﬁed covariates were considered to be clinicallyrelevant, based on their impact on simulated peginesatide exposure
(o730%) and Hb (o0.2 g/dL) levels.
http://dx.doi.org/10.1016/j.krcp.2012.04.496
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A post-menopausal patient with normal kidney function was referred to
our hospital because of severe lumber pain. She had been treated by
initially oral, and then by intravenous iron for longer than ﬁve years for the
treatment of iron deﬁciency anemia due to recurrent GI bleeding. On
admission, multiple lumber bone fracture with low bone mineral density
was conﬁrmed. Laboratory tests revealed severe hypophosphatemia (1.6
mg/dl) with slight decrease of calcium ion level. Serum levels of 25D and
1,25D were low normal, while increase of intact PTH (83.9 pg/ml) and
FGF23 (60 pg/ml) were observed. After terminating intravenous iron
supplement, her symptoms and hypophsophatemia were gradually
normalized with oral active vitamin D treatment. Although we could not
completely exclude the contribution of disturbed iron absorption from the
intestine, damages of proximal tubular cells by iron, and osteomalacia
caused by the deposition of iron, increased FGF23 level may have played
critical roles in the development of severe hypophosphatemia in this
patient. Such hypophosphatemia due to high FGF23 has recently been
reported in patients treated by intravenous sacharated ferric oxide.
http://dx.doi.org/10.1016/j.krcp.2012.04.497174
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Within the US, the policies at dialysis facilities differ as to whether patients
(pts) are permitted to eat or not while being treated. The Eating At Treatment
(EAT) pilot program was designed to determine whether educating pts and
allowing them to eat on dialysis would reduce the number of missed meals on
dialysis days and potentially improve nutritional status. The EAT questionnaire
was developed as a tool to assess eating habits of pts on days they received
dialysis treatment vs non-treatment days. Seven Registered Dietitians (RDs)
administered the EAT questionnaire to 61 pts.
Patients reported eating a different number of meals/day (2.32 vs 2.69) and
snacks/day (1.09 vs 1.36) on treatment vs non-treatment days, respectively. Of
the pts who ate at the dialysis facility, 86% reported that they ate during
treatment as opposed to before or after treatment. Of the pts who did not eat at
the dialysis facility, the most common reported reasons were that they were
not hungry (63%) or reported an adverse event (eg., stomach pain, risk of
diarrhea, hypotension) (20%). Reported dietary intake from 37 pts who ate
during dialysis was scored by RDs for protein and kcal content. Adequate intake
was set at 4 200 kcal for calorie intake and 4 10 g of protein for protein
intake. Nineteen (51%) pts reported adequate kcal intake, while only 12 (32%)
pts reported adequate protein intake.
Based on results obtained from this small pilot questionnaire, pts reported
eating less on treatment days vs non-treatment days. In addition, pts reported
that their intake at treatment was low in protein. This questionnaire has proven
to be an effective tool that is easy to administer and score (total time 12min/
pt) for providing insight into the eating habits of pts receiving dialysis
treatment. An opportunity exists for educating pts through nutritional
counseling about increasing their protein and kcal intake on treatment days.
Distribution of this questionnaire to a large number of dialysis pts may prove
useful for reevaluating policies regarding eating at dialysis centers.
http://dx.doi.org/10.1016/j.krcp.2012.04.498
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